Posts for MediWound Ltd. ($MDWD)

MediWound Ltd. files Form 6-K on Feb 12, 2025, announcing the VALUE Global Phase III trial for EscharEx® aimed at treating Venous Leg Ulcers, marking a significant milestone.

MediWound Ltd. presents its 2025 financial outlook and product details in a recent Form 6-K report. Key insights for investors available online.

Discover the outcomes of MediWound Ltd.'s December 2024 shareholder meeting, including the adoption of the 2024 Share Incentive Plan and key voting results.